Bivalirudin as an Alternative Anticoagulant for Cardiopulmonary Bypass During Adult Cardiac Surgery-A Change in Practice

Case report published in J Extra Corpor Technol (2017)

Última actualización: June 18, 2026Revisado por: ASH Editorial Board

Research article — evidence reviewArticle reference

Evidence: Case reportDesarrollo de fármacosEnsayos clínicosGatt P et al. · J Extra Corpor Technol, 2017

Abstract

The referral of patients for open heart surgery, presenting with a history of heparin hypersensitivity instigated a multidisciplinary effort to find an alternative anticoagulant to heparin. The various options mentioned in the literature call for changes in the routine practice of open heart surgery on cardiopulmonary bypass. These changes involve mostly the perfusion setup and conduct on bypass and to a lesser extent the anesthetic and surgical practice. Nevertheless, the different professions involved in the cardiac surgical firm discussed the proposed changes in a multidisciplinary effort. A new protocol was drafted, endorsed, and executed. The authors highlight these changes and their successful use in the subsequent case study.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeCase ReportsJournal Article

Indexed MeSH termsAgedAlgorithmsAnticoagulantsCardiopulmonary BypassCombined Modality TherapyCoronary Artery DiseaseDrug Administration ScheduleHirudinsHumansMalePeptide FragmentsRecombinant Proteins

Resumen

Multidisciplinary protocol for using bivalirudin in adult cardiopulmonary bypass for heparin-hypersensitivity patients.

Por qué esto importa para la hirudoterapia

This case report describes a multidisciplinary effort to develop and implement a clinical protocol for using an alternative anticoagulant to heparin in patients presenting with heparin hypersensitivity who required cardiopulmonary bypass for open heart surgery. The authors detail modifications to perfusion setup and bypass conduct and report successful execution of the protocol in a subsequent case. The abstract does not name the specific anticoagulant used, nor does it mention leeches, hirudotherapy, hirudin, or leech-secretome components. CAVEAT: This is a single case report with no control group; the abstract provides insufficient detail to establish any connection to ASH's domain, as the alternative anticoagulant is not identified.

Citación

Bivalirudin as an Alternative Anticoagulant for Cardiopulmonary Bypass During Adult Cardiac Surgery-A Change in Practice.

Gatt P et al. · J Extra Corpor Technol, 2017

DOI

Contexto clínico relacionado

Explore cómo esta investigación se conecta con la práctica clínica

Drug Pipeline Drug Development Direct Thrombin Inhibitors Clinical Evidence Clinical Applications Hirudin Anticoagulation Compounds Bivalirudin Hemostasis Cardiovascular Cardiology Otolaryngology Pulmonology

Aviso legal — investigación y educación

La información en esta página se proporciona únicamente con fines educativos e informativos y no constituye asesoramiento médico, diagnóstico o recomendaciones de tratamiento. Los resúmenes de evidencia clínica reflejan la literatura publicada revisada por pares y no implican eficacia terapéutica fuera de los contextos autorizados por la FDA.

La autorización FDA 510(k) para sanguijuelas medicinales se limita a indicaciones específicas. Las aplicaciones en investigación y fuera de indicación se identifican como tales. Los profesionales deben consultar las directrices vigentes de la FDA, los protocolos institucionales y las normativas estatales aplicables antes del uso clínico.

ASH apoya la evaluación rigurosa basada en evidencia de todas las aplicaciones de hirudoterapia mediante ensayos clínicos controlados e investigación revisada por pares.

Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: June 18, 2026